CREDIT SUISSE mentions Admedus again!

Well renowned international research house Credit Suisse.pdf has mentioned Admedus
again. The investment bank side of Credit Suisse is a big deal in New York. This kind of exposure is another great endorsement of the progress Admedus are making. Imagine being mentioned in the same article as Medtronic, Abbott, Boston Scientific and Edwards Lifesciences.

This is the heading:

TAVR & Surgery During COVID-19Interim Protocol for TAVR Patients Emerging; Elective Surgeries Down; Patient ‘Visits’ Move to Telemedicine; PPE Supply Remains Tight

This is the mention:

Dr. Thourani’s Brief Thoughts on ACC: Although we spent the vast majority of the conf call discussing matters related to COVID-19, we view Dr. Thourani’s overall view of the key results presented to TAVR at this year’s Virtual ACC meeting as being more or less in-line and as expected. EW’s PARTNER 3 two-year results demonstrated that TAVR maintained statistical superiority over SAVR at two years for composite primary endpoint and rehospitalization. All-cause mortality and stroke at two years were no longer statistically superior to surgery, but they remain numerically better and statistically ‘non-inferior’ (i.e. statistically equivalent). Dr. Thourani believes (as we do) that if TAVR remains ‘statistically equivalent’ over a 2-3 year period relative to surgery, it will still remain the preferred treatment for patients, given the avoidance of surgery and the near-term risks of complications, mortality and stroke, which remain statistically higher in the first year. However, durability and long-term outcomes remain important since an increasing portion of U.S. TAVR cases fall into the low-risk category and are, in fact, younger. New technologies to enhance intermediate and long-term durability of these valve systems could become increasingly important, even if the data ultimately shows valve deterioration consistent with surgical valves. On this front, Dr. Thourani mentioned that he looks forward with interest to further evidence supporting new technologies to improve long-term durability, including Admedus’ ADAPT tissue treatment technology (AHZ.AX, not covered), which has begun to gain interest and attention among other clinicians and thought-leaders we’ve spoken to over the past several months.

Companies mentioned:

5 April 2020Companies Mentioned (Price as of 03-Apr-2020) Abbott Laboratories (ABT.N, $79.45)Admedus (AHZ.AX, A$4.82)Boston Scientific Corp. (BSX.N, $31.17)Edwards Lifesciences Corp. (EW.N, $189.07) Medtronic Plc (MDT.N, $86.27)